Toshiba America Medical Systems has released a new CT scannerthat moves the spiral scanning technology of the company's premiumXpress/SX scanner to a more compact package. Xpress/GX is a one-secondscanner that is 50% smaller and 30% lighter than most
Toshiba America Medical Systems has released a new CT scannerthat moves the spiral scanning technology of the company's premiumXpress/SX scanner to a more compact package. Xpress/GX is a one-secondscanner that is 50% smaller and 30% lighter than most systemson the market, according to the Tustin, CA, vendor.
Toshiba achieved space savings by incorporating the scanner'sx-ray generator into the gantry. The system also uses a new opticaldata transmission technology for transferring data from rotatingx-ray detectors to the display. Xpress/GX can be installed intoa 10 x 20-foot room and weighs just over 4100 pounds.
The scanner employs nearly 900 solid-state detectors, has aspatial resolution of 18 lp/cm and ships standard with a 3.5-million-heat-unit x-ray tube. It can resolve objects as smallas 2.5 mm at 0.25% contrast, and standard image reconstructiontakes five seconds. Xpress/GX will carry a list price of $890,000.
Toshiba's new scanners, including the Xpress/SX, have improvedthe company's CT market-share position this year, according toJohn Ariatti, vice president of marketing. Toshiba estimates itsU.S. market share at just under 10%, several points higher thanits share last year, Ariatti said.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.